New hope for tough lymphoma: experimental drug KK2223 enters human testing
Disease control
Not yet recruiting
This early-phase study tests a new drug called KK2223 in about 72 adults with T-cell lymphoma that has returned or not responded to prior therapy. The main goals are to find a safe dose and understand side effects. Participants will receive the drug and be closely monitored for s…
Phase: PHASE1 • Sponsor: Kyowa Kirin, Inc. • Aim: Disease control
Last updated May 10, 2026 14:39 UTC